IL6 and non-small cell lung carcinoma: Metformin has been reported to sensitize EGFR-TKI–resistant NSCLC through the inhibition of IL-6 or AMP-activated kinase signaling [110,111] and increase the radiosensitivity of NSCLC through ATM and AMPK [112].